RxDoctor Payments Data

Rebecca Vonarx, PA

Physician Assistant · Centre Hall, PANPI 1831644210

Payments from drug & device makers

$2,377in general payments, 2019–2025

Across 117 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$479
  • Neurocrine Biosciences, Inc.$373
  • AbbVie$322
  • Alkermes, Inc.$250
  • Ironshore Pharmaceuticals Inc.$195
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$194
  • plus $564 from 6 others

What the payments were for

  • Food & beverage$2,32898%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,377 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$24,916
Medicare patients
74
Services billed
315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate14$92,921
RexultiBrexpiprazole103$88,422
AustedoDeutetrabenazine13$82,848
VraylarCariprazine Hcl44$60,587
Abilify MaintenaAripiprazole13$37,859
Invega SustennaPaliperidone Palmitate11$37,526
ClozarilClozapine13$31,036
Clozapine294$17,405
Clomipramine Hcl46$9,788
Divalproex Sodium ErDivalproex Sodium147$8,445
ViibrydVilazodone Hcl22$7,515
Chlorpromazine Hcl89$7,240
Lurasidone Hcl30$6,957
Duloxetine Hcl244$3,161
Quetiapine Fumarate288$2,997

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$172$130,44725 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$479$126,281116 claims
Teva Pharmaceuticals USA, Inc.Austedo$48$82,84813 claims
AbbVieVraylar, Viibryd$322$68,10266 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Centre Hall

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →